Table 4.
Multivariable linear regression for change in sleep quality from baseline to week 4, week 12, and week 24 among participants with available estimated dolutegravir AUC0-24 concentrations
| Multivariable associations Week 4 (n = 419) | Multivariable associations Week 12 (n = 411) | Multivariable associations Week 24 (n = 418) | ||||
|---|---|---|---|---|---|---|
| Coefficient (95% CI) | P valuea | Coefficient (95% CI) | P valuea | Coefficient (95% CI) | P valuea | |
| Age (per 10 years increase) | −0.205 (−0.389 to −0.021) | 0.029 | −0.142 (−0.319 to 0.035) | 0.115 | −0.043 (−0.228 to 0.142) | 0.646 |
| Sex | ||||||
| Female | Referent group | |||||
| Male | 0.060 (−0.235 to 0.354) | 0.690 | 0.002 (−0.290 to 0.295) | 0.987 | −0.019 (−0.320 to 0.281) | 0.899 |
| Baseline CD4 count (per 50 cells/mm3 increase) | 0.003 (−0.028 to 0.034) | 0.871 | −0.030 (−0.059 to −0.001) | 0.049 | −0.015 (−0.044 to 0.015) | 0.338 |
| Baseline HIV-1 RNA (per 1 log10 increase) | 0.095 (−0.117 to 0.306) | 0.379 | −0.023 (−0.238 to 0.193) | 0.837 | 0.069 (−0.124 to 0.261) | 0.484 |
| Arm | ||||||
| TAF | Referent group | |||||
| TDF | 0.205 (−0.078 to 0.487) | 0.155 | 0.187 (−0.097 to 0.471) | 0.197 | 0.023 (−0.266 to 0.313) | 0.875 |
| DTG AUC0-24 (mg·h/L) (per 1 log10 increase) | −0.552 (−1.343 to 0.239) | 0.171 | −0.854 (−1.703 to −0.005) | 0.049 | −0.096 (−0.854 to 0.663) | 0.804 |
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; DTG, dolutegravir; AUC0-24, area under the concentration-time curve; PK, pharmacokinetics.
a
P values <0.05 are shown in bold.